Search
IGC Pharma Inc
IGCAdd to Watchlist
0.286USD
+0.003+1.06%
Close 09-23 16:00（ET）
29.85MMarket Cap
LossP/E TTM
After-hours 18:30 (ET)0.286USD0.000
After-hours 18:30 (ET)About IGC Pharma Inc Company
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
IGC Pharma Inc Profile
Ticker SymbolIGC
Company nameIGC Pharma Inc
IPO dateApr 13, 2006
CEOMukunda (Ram)
Number of employees70
Security typeOrdinary Share
Fiscal year-endApr 13
Address10224 Falls Road
CityPOTOMAC
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code20854
Phone13015294996
Websitehttps://igcpharma.com/
Ticker SymbolIGC
IPO dateApr 13, 2006
CEOMukunda (Ram)
Company Executives of IGC Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ram Mukunda
Mr. Ram Mukunda
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
7.74M
+28.78%
Mr. Ram Mukunda
Mr. Ram Mukunda
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
7.74M
+28.78%
Ms. Claudia Grimaldi
Ms. Claudia Grimaldi
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
3.42M
+59.87%
Ms. Claudia Grimaldi
Ms. Claudia Grimaldi
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
3.42M
+59.87%
Mr. Richard K. Prins
Mr. Richard K. Prins
Independent Chairman of the Board
Independent Chairman of the Board
1.54M
+11.03%
Mr. Richard K. Prins
Mr. Richard K. Prins
Independent Chairman of the Board
Independent Chairman of the Board
1.54M
+11.03%
Mr. Terry L. Lierman
Mr. Terry L. Lierman
Independent Director
Independent Director
29.41K
--
Mr. Terry L. Lierman
Mr. Terry L. Lierman
Independent Director
Independent Director
29.41K
--
Congressman James (Jim) Moran
Congressman James (Jim) Moran
Independent Director
Independent Director
--
--
Congressman James (Jim) Moran
Congressman James (Jim) Moran
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ram Mukunda
Mr. Ram Mukunda
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
7.74M
+28.78%
Mr. Ram Mukunda
Mr. Ram Mukunda
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
7.74M
+28.78%
Ms. Claudia Grimaldi
Ms. Claudia Grimaldi
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
3.42M
+59.87%
Ms. Claudia Grimaldi
Ms. Claudia Grimaldi
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
3.42M
+59.87%
Mr. Richard K. Prins
Mr. Richard K. Prins
Independent Chairman of the Board
Independent Chairman of the Board
1.54M
+11.03%
Mr. Richard K. Prins
Mr. Richard K. Prins
Independent Chairman of the Board
Independent Chairman of the Board
1.54M
+11.03%
FAQs
Who are the top five shareholders of IGC Pharma Inc?
The top five shareholders of IGC Pharma Inc are: Mr. Ram Mukunda
How many institutions hold shares of IGC Pharma Inc (IGC)?
As of 2026Q1, 56 institutions hold shares of IGC Pharma Inc, with a combined market value of approximately 22.48M, accounting for 22.76% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2863363.00.
What is the biggest source of revenue for IGC Pharma Inc?
In 2026Q1, the Tolling/White labeling service business generated the highest revenue for IGC Pharma Inc, amounting to 256.00K and accounting for 96.60% of total revenue.